CTD 0 12.5/40 TAB

AboutCTD O 12.5/40 TAB is a combination medication containing Chlorthalidone (12.5mg) and Olmesartan (40mg). Chlorthalidone is a thiazide-like diuretic that acts by increasing the excretion of sodium and water, thereby reducing blood volume and peripheral vascular resistance. Olmesartan is an Angiotensin Receptor Blocker (ARB) that selectively blocks the AT1 receptor, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This dual mechanism provides a powerful and complementary approach to blood pressure control, making it highly effective for patients with essential hypertension who require more aggressive management than monotherapy can provide. The combination helps to achieve target blood pressure levels, reduce the risk of cardiovascular events, and protect vital organs from hypertension-related damage. Its once-daily administration supports patient adherence and simplifies the treatment regimen.UsesManagement of essential hypertensionReduction of cardiovascular morbidity and mortalityTreatment of fluid overload in specific conditionsAdjunctive therapy in heart failure managementDirections For UseTake one tablet orally once daily, preferably at the same time each day, with or without food.BenefitsProvides significant and sustained blood pressure reductionOffers comprehensive cardiovascular protectionConvenient once-daily dosing improves adherenceSynergistic action of two antihypertensive agentsHelps prevent hypertension-related organ damageWell-tolerated in many patient populationsSide EffectsDizziness or lightheadednessFatigue or weaknessHeadacheCough (less common than ACE inhibitors)Low blood pressure (hypotension)Electrolyte imbalances (e.g., hypokalemia, hyponatremia)Kidney dysfunction or increased creatinineMuscle cramps or painNausea or diarrheaIncreased uric acid levels (hyperuricemia)HyperglycemiaBack painSafety MeasuresAlcohol - Alcohol can potentiate hypotensive effects and increase the risk of dizziness. Use with caution.Pregnancy - Contraindicated during the second and third trimesters due to severe risk of fetal injury and death.Breastfeeding - Not recommended during breastfeeding as components may be excreted in breast milk. Consult a healthcare provider.Liver - Use with caution in patients with hepatic impairment; dose adjustment may be required.Kidney - Contraindicated in severe renal impairment; close monitoring of renal function is crucial.Lung - Generally safe, but monitor for electrolyte disturbances that could indirectly affect respiratory status.DisclaimerMedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.Our goal is to complement, not replace, the essential doctor-patient relationship.